The DESCAR-T registry has been created to meet a request from the French Health Authorities to collect data in order to consolidate the knowledge on the efficacy and safety at both short- and long-term of all CAR T-cell therapies marketed in France.
A project will analyse data on a large population that received CAR-T- in real-life settings, using the DESCAR-T registry, to get further insight into the safety of these therapies in lymphoma. It will focus on the deaths that occur following a treatment by CAR T-cells and that are not related to a progression of the disease. This project will help describe and better identify deaths that may be caused by these therapies in the short and long terms. The results of this project will help improve the understanding of the benefit-risk profile of CAR-T cells.
This project started in May 2022 and will continue in 2023.
To the patients that received CAR-T, if you would like more information about the treatment of your data in the DESCAR-T Registry, you can contact the doctor at your centre of care for your CAR-T treatment or make a request at dpo@lysarc.org. You can find more details your rights regarding your data in the section “I am participating or have participated in a clinical trial“, or in the Patient Information Leaflet you received at the time of your inclusion in the registry.